Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265874 · ClinicalTrials.gov registry record · Phase 1
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
A Phase 1 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02265874 is a Phase 1 study that has completed, run by Ohio State University. The registered enrollment target is 50 participants.
The verdict
NCT02265874, a Phase 1 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. Sarcoidosis is a disease of unknown cause that leads to inflammation. This disease affects your body's organs.
Interventions
- DRUG Habitrol
- DRUG Placebo to Habitrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-10-21 |
| Est. Completion | 2021-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02265874
The ClinicalTrials.gov registry entry for NCT02265874 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Habitrol is the first listed.
NCT02265874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02265874 about?
NCT02265874 is a clinical study titled "Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study". The purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. Sarcoidosis is a disease of unknown cause that leads to inflammation. This disease affects your body's organs.
What is the current status of trial NCT02265874?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-10-21. Estimated completion is 2021-11-01.
What interventions are being tested in trial NCT02265874?
The interventions under investigation include: Habitrol (DRUG), Placebo to Habitrol (DRUG).
Who is sponsoring clinical trial NCT02265874?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.